Tailoring Treatment Strategies and Sequencing in HER2-Mutant Advanced NSCLC

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss the importance of biomarker testing in non–small cell lung cancer and tools for detecting HER2-mutant disease.

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss frontline therapy approaches in HER2-mutant non–small cell lung cancer and the evolving role of chemoimmunotherapy.

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss factors that inform sevabertinib and zongertinib treatment selection in HER2-mutant NSCLC.

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss toxicity management with TKIs in HER2-mutant non–small cell lung cancer.

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, examine sequencing considerations between tyrosine kinase inhibitors and antibody-drug conjugates in HER2-mutant non–small cell lung cancer.

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss how the NCCN Guidelines can help supplement HER2-mutant non–small cell lung cancer management decisions.

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss other potential treatment avenues to explore in HER2-mutant non–small cell lung cancer.